ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

ClinicalTrials.gov ID: NCT03390504

Public ClinicalTrials.gov record NCT03390504. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 24, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Study identification

NCT ID
NCT03390504
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
629 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Erdafitinib Drug
  • Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) Device
  • Pembrolizumab Drug
  • Vinflunine Drug

Drug · Device

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 22, 2018
Primary completion
Apr 14, 2024
Completion
Dec 30, 2026
Last update posted
Apr 12, 2026

2018 – 2026

United States locations

U.S. sites
26
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
Alaska Urological Institute dba Alaska Clinical Research Center Anchorage Alaska 99503
University of Calif Davis Medical Center Sacramento California 95817
St. Helena Hospital - Martin-O'Neil Cancer Center St. Helena California 94574
MedStar Georgetown University Hospital Washington D.C. District of Columbia 20007
University of Miami Sylvester Cancer Center Miami Florida 33136
Mid Florida Hematology Oncology Orange Florida 32763
Piedmont Cancer Institute Atlanta Georgia 30318-0922
Rush University Chicago Illinois 60612
Edward Hines Jr V A Hospital Hines Illinois 60141
Norton Cancer Institute Louisville Kentucky 40207
Maryland Oncology Hematology, PA Lanham Maryland 20706
University of Michigan Health System Ann Arbor Michigan 48109-5000
VA Sierra Nevada Health Care System Reno Nevada 89509
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Weill Cornell Medical College New York New York 10029
Montefiore Medical Center The Bronx New York 10461
Levine Cancer Institute, Carolinas HealthCare System Charlotte North Carolina 28204
W G Bill Hefner VA Medical Center Salisbury North Carolina 28144
Oncology Hematology Care Cincinnati Ohio 45242
The Center for Cancer and Blood Disorders Fort Worth Texas 76104
Texas Oncology-Memorial City Houston Texas 77024
MD Anderson Cancer Center Houston Texas 77030
Texas Oncology Tyler Tyler Texas 75702
INOVA Dwiight &Martha Schar Cancer Institute Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502
VA Puget Sound Healthcare System Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 319 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03390504, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced Apr 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03390504 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →